Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunome Inc.

9.69
-0.1800-1.82%
Post-market: 9.50-0.1874-1.93%19:31 EDT
Volume:580.88K
Turnover:5.66M
Market Cap:843.47M
PE:-3.10
High:10.03
Open:9.74
Low:9.60
Close:9.87
52wk High:16.73
52wk Low:5.15
Shares:87.05M
Float Shares:70.64M
Volume Ratio:0.86
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1265
EPS(LYR):-4.9960
ROE:-69.21%
ROA:-33.54%
PB:2.75
PE(LYR):-1.94

Loading ...

Company Profile

Company Name:
Immunome Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
131
Office Location:
18702 North Creek Parkway,Suite 100,Bothell,Washington,United States
Zip Code:
98011
Fax:
- -
Introduction:
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Directors

Name
Position
Purnanand D. Sarma
President, Chief Executive Officer and Director
John LaMattina
Director
Michael Lefenfeld
Director
Michael Rapp
Director
Michael Widlitz
Director
Philip Wagenheim
Director
Richard Baron
Director

Shareholders

Name
Position
Purnanand D. Sarma
President, Chief Executive Officer and Director
Richard F. Fitzgerald
Chief Financial Officer
Michael J. Morin
Chief Scientific Officer